INTRODUCTION

Despite the availability of many antiepileptic drugs, around 20-40% of newly diagnosed epilepsy patients will end up with refractory epilepsy.\(^1\)

Pathophysiology of epilepsy includes two sequential events: (a) Generation of a locus of abnormally increased neuronal excitability; (b) spread of this hyperexcitability across the neurons through hypersynchronization.\(^2\) None of the current anti-seizure drug targets the latter mechanism.

Gap junctions (GJs), which mediate electrotonic synaptic communication between neurons are involved in the process of hypersynchronization.\(^3\) The functional units of GJs are connexins (Cxs) (Figure 1).\(^4\) Of the 21 Cx subtypes described in humans, Cx-36 is the major neuron-specific Cx. Cx-36 is involved in seizure pathogenesis and
has been associated with juvenile myoclonic epilepsy. Quinine is a selective and reversible blocker of Cx-36.

Various studies have documented *in-vitro* and *in-vivo* anticonvulsant activity of quinine in animal models. However, there is a paucity of data wherein the anticonvulsant activity of quinine is compared with drugs currently used in treating epilepsy.

**MATERIALS AND METHODS**

This randomized, prospective, controlled, open-labelled animal study was conducted in Department of Pharmacology, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, after obtaining Institutional Animal Ethics Committee approval.

Healthy albino Sprague-Dawley rats (*n* = 72) of either sex weighing 150-200 g, inbred in the institutional animal house, were used for the study. The animals were given care as per Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines.

Normal saline vehicle was used to prepare drug solutions of quinine (N.I Pharmaceuticals, India), valproate (Sun, India), phenytoin (Abbott, India), and pentyleneetrazole (PTZ) (Sigma, USA). The three doses of quinine used in the study (28, 35 and 42 mg/kg) were calculated from doses used in a similar study where mice were used; the dose of PTZ (90 mg/kg) was the same as used in a similar study. Doses of valproate and phenytoin (90 mg/kg and 27 mg/kg respectively) were extrapolated from their average therapeutic dose in humans (1000 mg and 300 mg respectively). PTZ was administered subcutaneously into the scruff of the neck; all the other drugs were administered intraperitoneally.

**PTZ model:** The animals were injected drugs/vehicle as per study groups. Thirty minutes later PTZ was administered, and the animals were observed for 30 minutes.

The occurrence of clonic seizure for more than 5 seconds was taken as a positive seizure response; abolition of clonic seizure was considered as protection against PTZ seizures. Seizure occurrence (present/absent), seizure latency (time for seizure onset) in seconds, and duration of the clonic phase of the seizure in seconds were recorded.

Maximal electroshock (MES) model: Well before the experiment, animals were acclimatized to the feel of ear-clip electrodes; rats that struggled excessively were discarded. The electroconvulsiometer (Bijou, Prasad Scientific) was calibrated at 150 mA/100 V/0.2 s. The animals were injected drugs/vehicle as per study groups. Thirty minutes later, the rats were subjected to electric shock, and the resultant convulsions were timed. The occurrence of a hind limb tonic extension (HLTE) was taken as a positive response for MES; abolition of HLTE was taken as protection against MES seizures. HLTE occurrence and duration of HLTE in seconds were recorded.

Statistical analysis was performed using “Graphpad Prism 5” (San Diego, California, USA). For comparison between groups, one-way ANOVA was used with post-hoc Tukey’s test. *P* < 0.05 was considered as significant.

**RESULTS**

**PTZ model (Table 1)**

**Seizure occurrence**

Seizures were seen in all the animals in P0 group and PC (control group in the PTZ arm) group. Valproate prevented seizure occurrence in 4/6 rats (66.67% seizure protection). Quinine 35 mg/kg and 42 mg/kg prevented seizures in 2/6 and 3/6 rats, respectively (33.33% and 50% seizure protection respectively). Quinine 28 mg/kg did not prevent seizure occurrence.

**Seizure latency and duration**

There was no significant difference in the mean seizure latency and mean seizure duration between the two control groups; normal saline group was considered as a control group for further analysis.

Compared with control, valproate significantly prolonged seizure latency and shortened seizure duration (*P* < 0.001). Quinine 28 mg/kg did not prolong seizure latency or shorten seizure duration significantly (*P* > 0.05); the other two doses showed significant prolongation of seizure latency (*P* < 0.001 in both doses) and shortening of seizure duration (35 mg/kg: *P* < 0.01; 42 mg/kg: *P* < 0.001).
When the seizure latency and seizure duration seen with valproate were compared with those observed with the three doses of quinine, there was a significant difference with quinine at 28 mg/kg ($P < 0.001$); however, the difference seen with the other two doses of quinine were not significant (Figure 2a and b).

There was a significant difference between mean seizure latency and seizure duration values of the 28 mg/kg (P1) group and the other two quinine groups (seizure latency: $P < 0.01$ with 35 mg/kg group; all other comparisons: $P < 0.001$), but there was no significant difference between the mean values of 35 mg/kg (P2) and 42 mg/kg (P3) groups (Figure 2c and d).

**DISCUSSION**

Quinine is a reversible blocker of GJs formed by Cx-36, and has a low selectivity for Cx-50, but not other Cx protein subtypes. Studies have demonstrated that quinine suppresses ictal activity without affecting normal neuronal function in both *in-vitro* (rat hippocampal slice preparation) and *in-vivo* (4-aminopyridine induced epilepsy model) conditions. Further, trimethylamine, a specific opener of GJ channels negates quinine’s seizure protective activity. Thus, the anticonvulsant activity seen with quinine is most probably due to its effects on the GJs.

In our study, we found that quinine at doses of 35 mg/kg and 42 mg/kg, but not 28 mg/kg protects rats against PTZ-induced seizures, and the efficacy was comparable to valproate. Similar to our study, Nassiri-Asl *et al.* had reported that higher doses (50 and 60 mg/kg in mice), but not lower doses (20, 30 and 40 mg/kg in mice), of quinine had anticonvulsant activity in PTZ model. Our study did not demonstrate seizure protection by any of the three doses of quinine in the MES model. Wambebe *et al.* had also similarly reported that quinine did not have anticonvulsant activity in MES model in mice. Thus, quinine appears to have anticonvulsant activity in the PTZ model at higher doses, but not in the MES model. This differential efficacy of quinine can be accounted for by two reasons:

a. Quinine might be having activity in MES model at doses that are different from those considered in the present study.

b. Among the various drugs known to block GJs, carbenoxolone is known to be a non-specific GJ inhibitor. Carbenoxolone is reported to control seizures induced by both MES and PTZ models. Quinine, on the other hand, inhibits only those GJs that are formed by Cx-36 and Cx-50. It might be possible that the pathophysiology of MES-induced seizures involves GJs formed by Cxs other than Cx-36 and Cx-50.

Studies with a larger sample size, and a wider range of doses of quinine, can confirm its usefulness in PTZ model, and explore its potential in the MES model and in other seizure models as well.

**Table 1: Seizure occurrence, mean seizure latency and duration in PTZ model**

<table>
<thead>
<tr>
<th>Group</th>
<th>Drug</th>
<th>Seizure occurrence</th>
<th>Seizure latency (sec)$^a$</th>
<th>$P$ value</th>
<th>Seizure duration (sec)$^a$</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC</td>
<td>Control: Normal saline</td>
<td>6/6</td>
<td>129.00±52.66</td>
<td>-</td>
<td>38.33±15.65</td>
<td>-</td>
</tr>
<tr>
<td>P0</td>
<td>No drug</td>
<td>6/6</td>
<td>127.67±52.12</td>
<td>&gt;0.05</td>
<td>43.17±17.62</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>P5</td>
<td>Standard: Valproate 90 mg/kg</td>
<td>2/6</td>
<td>839.67±342.79</td>
<td>&lt;0.001$^*$</td>
<td>8.67±5.54</td>
<td>&lt;0.001$^*$</td>
</tr>
<tr>
<td>P1</td>
<td>Quinine 28 mg/kg</td>
<td>6/6</td>
<td>264.17±107.85</td>
<td>&gt;0.05</td>
<td>37.33±15.24</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>P2</td>
<td>Quinine 35 mg/kg</td>
<td>4/6</td>
<td>633.17±258.49</td>
<td>&lt;0.001$^*$</td>
<td>13.83±5.65</td>
<td>&lt;0.01$^*$</td>
</tr>
<tr>
<td>P3</td>
<td>Quinine 42 mg/kg</td>
<td>3/6</td>
<td>711.17±290.33</td>
<td>&lt;0.001$^*$</td>
<td>10.67±4.35</td>
<td>&lt;0.001$^*$</td>
</tr>
</tbody>
</table>

*N=6 in each group. One-way ANOVA followed by Tukey’s test.$^a$Means±SEM, $^*$Statistically significant (comparison with PC group), SEM: Standard error of the mean, PTZ: Pentylenetetrazole*
An ideal candidate antiepileptic drug should have minimal adverse effects for ensuring better patient compliance. Though quinine is associated with many side-effects, its novel anticonvulsant mechanism cannot be neglected keeping in mind the ever-increasing problem of refractory epilepsy. In this context, quinine might be useful as a rescue drug for refractory seizures and treatment-resistant status epilepticus, pending results from appropriate studies in animal models. Another hope for the future is that newer molecules that have the anticonvulsant properties of quinine without its adverse effects be developed.

CONCLUSION

Quinine has anticonvulsant activity in albino Sprague-Dawley rats in the PTZ seizure model (at higher doses) but not in the MES seizure model, and that this anticonvulsant activity is comparable to that seen with valproate.

ACKNOWLEDGEMENTS

The authors acknowledge the cooperation extended by the teaching and non-teaching staff at the Department of Pharmacology at Grant Govt Medical College, Mumbai.

Conflict of Interest: None.

REFERENCES

5. Srinivas M, Hopperstad MG, Spray DC. Quinine blocks specific gap junction...


